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Perception of drug teratogenicity among
general practitioners and specialists in
obstetrics/gynecology: a regional and
national questionnaire-based survey
Charlotte Gils1, Anton Pottegård1,2, Zandra Nymand Ennis1,2 and Per Damkier1,2*
Abstract
Background: Estimating the true risk of fetal malformations attributable to the use of medications is difficult and
perception of risk by health professionals will impact their counseling and treatment of patients who need medication
during pregnancy. The objective of this study was to assess the perception of the teratogenic risk of 9 commonly and
3 rarely prescribed drugs among general practitioners and specialists in obstetrics/gynecology.
Methods: All 811 general practitioners in the Region of Southern Denmark and all 502 specialist obstetricians/
gynecologists in Denmark as a whole were invited to participate in the study based on an online questionnaire.
Medians and interpercentile ranges of the perceived background risk and perceived risks for each of the drugs were
included in the questionnaire.
Results: One hundred forty three (18 %) general practitioners and 138 (27 %) obstetricians/gynecologists
participated. Estimates provided by the participants were generally in accordance with current knowledge
of drugs with established safety during pregnancy. Perceptions of risks associated with warfarin and retinoid
exposure were severely underestimated.
Conclusions: Understanding of teratogenic background risk and specific risks associated with in utero exposure to 12
different drugs generally approached the established knowledge. The risk associated with warfarin and retinoid
exposure was severely underestimated by both groups of health care professionals, while general practitioners
specifically overestimated the risk of sertraline and citalopram to some extent. In Denmark, general practitioners
can prescribe antidepressants, and even minor misconceptions of the teratogenic potential of citalopram and
sertraline may be of clinical relevance. In Denmark, systemic retinoids can only be prescribed by a dermatologist,
and warfarin treatment is only rarely initiated in women of the fertile age without involvement of specialists in
internal medicine. Hence, the active knowledge on the teratogenic potential of these drugs is likely to be less
accurate among general practitioners and obstetricians/gynecologists; although still of clinical importance since
these specialists are largely involved in the counselling of pregnant women.
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Background
Knowledge about the risk of medications being
teratogenic became apparent after the thalidomide
disaster [1, 2] some 50 years ago. The tragedy gave
rise to concerns on the safety of drugs during preg-
nancy and prompted international agencies to develop
systematic preclinical reproductive testing protocols
[2]. Estimating the true risk of fetal malformations at-
tributable to the use of medications is difficult and
controversial. While randomized controlled trials are
seen as the gold standard for assessing safety and effi-
cacy of medications, pregnant women are routinely
excluded from such trials [3]. This places a heavy re-
liance on observational studies and pharmacoepide-
miological data to provide evidence in support of
informed decision making on medication use during
pregnancy [3]. Perception of risk by health professionals
will impact their level of counseling and treatment of pa-
tients who need medication during pregnancy. Overesti-
mating this risk can lead to insufficient treatment of
patients, whereas underestimating may lead to hazardous
practice. Legal medical issues may additionally complicate
matters, and in case of Bendectin such issue led to the
market withdrawal of a documented safe and effective
product [4]. Perceptions of risk by patients impact their
decision on whether or not to use medicine during preg-
nancy, and the risk perceived by patients has been shown
to be heavily dependent on the information received from
their physician [5–7]. In recent surveys, 77 % of women
stated that they needed information about drug use during
their pregnancy, and 62 % of women believed it would be
better for the fetus if they refrained from using drugs that
they would otherwise have used if not pregnant [8, 9].
Teratogenic risk perception among health care profes-
sionals has only been subject to small-scale studies mostly
pertaining to general practitioners (GP) while only about
200 obstetricians/gynecologists (OB/GYN) have been sub-
ject to such study on teratogenic drug risk-perception on
a world-wide scale [10–15].
Aim of the study
The purpose of this study was to investigate the perception
of teratogenic risk of nine different commonly and three
rarely prescribed drugs among all GP in the Southern Re-
gion of Denmark and all OB/GYN in Denmark.
Methods
Study population
We included two groups of health professionals: All GP
(n = 811) in the Region of Southern Denmark (approxi-
mately 22 % of the Danish population) and all OB/GYN
holding a specialist authorization in Denmark (n = 502).
The demographic characteristics, patterns of health care
utilization and medication use are very homogenous in
Denmark, and the Region of Southern Denmark com-
pares well to other regions [16]. Adherence to RATS
guideline is documented in Additional file 1.
Data collection
Information was gathered by anonymous self-completed
questionnaires. The questionnaire was developed through
SurveyXact and was made available at a website for inter-
net surveys (https://www.survey-xact.dk). An invitation to
the study, including a link and a code to the questionnaire,
were sent to the study participants by mail. Email ad-
dresses could not be obtained as the respective organiza-
tions declined to release email addresses for the purpose
of this study. The online questionnaire was accessible
from November 19, 2012 to February 28, 2013. Transla-
tions of the cover letter to participating physicians and the
questionnaire are provided in Additional file 2.
Measurements of risk perception
The participants were asked to estimate the overall risk
of malformations in the background population. To
evaluate the perception of the teratogenic risk of specific
medications during pregnancy, the participants were
asked to give their best estimate based on their active
knowledge. Estimates were to be entered as an integer
between 0 and 100 %, without using references of any
kind while spending less than 5 min to complete the sur-
vey. The survey comprised drugs with documented no
or minor increased risks of teratogenicity (phenoxy-
methylpenicillin, metoclopramide, citalopram and sertra-
line representing selective serotonin reuptake inhibitors
(SSRIs), benzodiazepines, inhalation glucocorticoids, flu-
conazole, and lamotrigine) [17–19], one drug with insuffi-
cient data for risk estimation (quetiapine) [20] and drugs
with documented increased risk (retinoids, warfarin and
thalidomide) [17–19]. The “minor” risk designation is
covering some discrepancies and controversy on risk esti-
mation with respect to SSRI exposure and risk of cardio-
vascular malformations. No more than a 1.71-fold (the
upper bound of the 95 % CI) increased risk of cardiovas-
cular malformations and no more than a 1.26-fold (the
upper bound of the 95 % CI) increased risk of overall
major malformations, using the most comprehensive data
from meta-analysis data [21] and a recent study compris-
ing all Nordic data available appears likely [22].
For all drugs, the most common trade names were stated
in the questionnaire together with the generic names.
Data analysis
The questionnaires were analyzed by standard non-
parametric descriptive statistics, using STATA release
12.0 (StataCorp, College Station, TX, USA). The Wilcoxon
Rank-Sum Test was used for inferential statistics compar-
ing the responses between GP and OB/GYN.
Gils et al. BMC Pregnancy and Childbirth  (2016) 16:226 Page 2 of 7
Results
One hundred forth three (18 %) GP and 138 (27 %) OB/
GYN answered the questionnaire. Responses from 5 GP
were excluded as they had entered baseline malforma-
tion rates of 100 % or higher. Among the remaining GP,
28 had answered less than half the questions, 24 had an-
swered more than half but not all questions and 91 had
answered all questions. The corresponding values among
OB/GYN were 29, 34 and 75. Sensitivity analysis with
respect to numbers of questions answered did not alter
the results (data not shown). A substantial proportion of
responders had entered values for risks associated with
specific drug exposure as excess risk (relative to back-
ground risk) rather than absolute risks. In these cases,
values entered for teratogenic risks associated with spe-
cific drug exposures were lower than the values entered
for the overall background risk. In such cases, we added
the risk value entered for risk associated with the spe-
cific drug exposure to the value entered for the overall
background risk. We corrected the values for 84 (59 %)
of GP and 63 (46 %) of OB/GYN.
The results are presented in Table 1 and illustrated in
Figs. 1, 2 and 3. Generally, the median values of risk per-
ception indicate a realistic perception of drugs with
established safety. Notably, both GP and OB/GYN had
perceptions of teratogenic potential for retinoids and
warfarin that were substantially below the risk docu-
mented in the literature [17, 18]. The distribution of per-
centiles demonstrated a greater variability in responses
for the OB/GYN population compared to the GP re-
sponses. Statistically different perceptions of teratogenic
potential were found for metoclopramide, citalopram/
sertraline, benzodiazepines, quetiapine, warfarin and ret-
inoids with GP generally giving higher risk estimates. In
terms of absolute differences, median values were small
with the largest differences being for retinoids, warfarin
and citalopram/sertraline.
Discussion
This is one of the largest systematic surveys on risk per-
ception following in utero exposure to drugs among
health care professionals reported in the literature, and
the only study reporting on a nation-wide basis. Overall,
the responses were quite comparable with both between
GP and OB/GYN responders and compared to literature
data, though the variation in risk perception appeared
somewhat larger among GP. Some statistically significant
differences for individual drugs materialized, as GP
tended to slightly overestimate the risk associated with
exposure to citalopram/sertraline, metoclopramide and
benzodiazepines. Both GP and OB/GYN appeared to over-
estimate risk associated with lamotrigine. Lastly, we found
a substantial underestimation between the perceived risk
for retinoids and warfarin and the risk documented in the
literature among both GP and OB/GYN responders.
Generally, our results demonstrate a better under-
standing of teratogenic potential that otherwise reported
in the literature. In a Spanish study from 2001, percep-
tion of malformation rates following in utero exposure
were acetaminophen (5 %), amoxicillin (6 %), metoclo-
pramide (14 %), benzodiazepines (10 %), warfarin (53 %),
etretinate (96 %), and thalidomide (82 %) among 104
physicians [10]. Damase-Michel et al. found perception
of malformation rates for acetaminophen (20 %), amoxicil-
lin (14 %), metoclopramide (37 %), bromazepam (28 %),
warfarin (59 %), isotretionin (89 %), and thalidomide
(92 %) among 103 GP in a French region [11]. Con-
trary to these rather substantial overestimations, 74
Table 1 Perception of teratogenicity among GP and OB/GYN responders according to drug
Drug GP responders OB/GYN responders p-valuea
Median & [50 %] and 90 % IPR Median & [50 %] 90 % IPR
Acetaminophen 2.0 [1.0–5.0]; 0.4–16 2.5 [1.0–4.0]; 0.5–5.0 0.41
Phenoxymethylpenicillin 2.0 [1.0–5.0]; 0.1–6.0 2.0 [1.0–3.0]; 0,1–5,0 0.29
Metoclopramide 3.0 [1.0–5.0]; 0.20–7.0 2.0 [1.0–4.0]; 0.5–5.0 0.02
Citalopram/sertraline 4.0 [2.0–6.0]; 0.8–10.0 3.0 [2.0–5.0]; 0.5–6.0 0.02
Benzodiazepines 3.0 [1.0–5.0]; 0.5–8.0 2.5 [1.0–4.0]; 0.5–5.0 0.03
Inhaled glucocorticoids 3.0 [1.0–5.0]; 0.2–5.5 2.0 [1.0–3.0]; 0.5–5.0 0.54
Fluconazole 3.0 [1.5–5.0]; 0.5–7.0 2.5 [1.1–4.0]; 0.5–6.0 0.45
Quetiapine 5.0 [2.0–7.0]; 1.0–10 3.0 [1.5–5.0]; 0.5–6.0 0.001
Lamotrigine 5.0 [2.1–6.0]; 1.0–12 4.0 [2.0–5.0]; 0.6–7.0 0.25
Thalidomide 20 [10–50]; 5.0–60 20 [9.0–45]; 5.0–50 0.14
Warfarin 3.0 [1.5–5.0]; 0.5–10 5.0 [2.1–7.0]; 1.0–15 0.01
Retinoids 10 [5.0–20]; 1.6–50 5.0 [2.1–10]; 1.0–30 0.001
Background incidence 2.0 [0.5–4.0]; 0.02–5.0 2.0 [1.0–3.0]; 0.03–4.0 0.36
[50 %] and 90 % IPR: 50 % and 90 % interpercentil ranges. a: Wilcoxon signed rank sum test
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Fig. 1 Distribution of perceived background risk. Distribution of GPs (grey) and OB/GYN (white) perception of the overall risk of congenital
malformations in the background population
Fig. 2 Perception of background risk and for drugs with no or minor excess risk. Perception of teratogenic risk by GPs (grey) and OB/GYN (white)
of drugs known to be safe during pregnancy and the overall background incidence. Boxplot with medians and 50 % interpercentil ranges with
whiskers from the 10th to 90th percentiles. Statistically significant p- values are indicated
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Norwegian GP, assigned low values (below 1.5 using a
visual analogue scale from 0 to 10) for teratogenic
risk perception for metoclopramide, acetaminophen
and pivmecillinam, while escitalopram was rated 3.7
[12]. In a recent Brazilian study, more than 50 % of
GP and obstetricians asked (total n = 80) had a per-
ceived risk of congenital malformations of more than
5 % associated to first-trimester exposure to antide-
pressants, antipsychotics, benzodiazepine and anticon-
vulsants [13]. Serious overestimation of teratogenic
risks associated with radiography and CT-scan during
early pregnancy by GP and OB/GYN has also been
reported [14]. The overall reasonable risk estimates
from the responders in our study may to some extent
be attributed to selection bias (see study limitations
below), but dissemination of relevant information in a
systematic and useable form is likely a contributing
factor [23–25]. The by far most commonly used Danish
drug information resource by health care professionals
was completely restructured in 2005 with respect to preg-
nancy and lactation recommendations [19]. This Danish
online analogue to the Physicians’ Desk Reference has
since 2005 implemented a transparent and uniform algo-
rithm, which provides the clinician with information on
the level of scientific evidence; risk estimations and a clin-
ical recommendation (see Additional file 3 for a transla-
tion of these principles).
The difference in perception of the teratogenic poten-
tial for citalopram and sertraline between GP and OB/
GYN is noteworthy for several reasons: The issue of
SSRIs during pregnancy has been subject to an extensive
coverage within the health care community [21–32].
Numerous data are available and a recent comprehen-
sive meta-analysis documented more than 56,000 ex-
posed pregnancies [21]. This analysis found no overall
increased risk of major congenital malformations (OR
1.07, CI 0.99–1.17), while some excess risk (OR 1.36, CI:
1.08–1.71) appears likely with respect to cardiac malfor-
mations. A complete analysis from register data in all
Nordic countries comprising almost 37000 exposed
pregnancies found largely comparable estimates. The
overall major malformation risk was slightly increased
(OR 1.13, CI: 1.06–1.20) and the risk of cardiovascular
malformations was similar (OR 1.15, CI 1.05–1.17) [22].
Interestingly, the latter signal disappeared completely in
a subsequent sibling-controlled analysis. Another recent
case-control study based on EUROCAT register data
found a comparable level of association for overall car-
diovascular risk (OR 1.41, CI 1.07–1.86) with no appar-
ent specific signals for paroxetine and fluoxetine [29].
The EUROCAT data were not subject to any covariate
control analysis, and may be subject to reporting and
observer bias as these data are typically only reported
from certain regions in participating countries. This is
quite different from the Nordic dataset, which represents
a complete cohort of all exposed pregnancies in the
Nordic countries [22]. It should be noted that there
is some overlap of data among these studies, as data
from the Nordic countries to a varying degree con-
tribute to all three analyses. While overall no clinic-
ally important risk of major congenital malformations
following first-trimester in utero exposure to SSRIs
has materialized from the best meta-analyses available,
a slightly increased relative risk of cardiovascular
Fig. 3 Perceptions of risk for known teratogenic drugs. Perception of teratogenic risk by GPs (grey) and OB/GYN (white) of drugs with documented
teratogenic potential. Boxplot with medians and 50 % interpercentil ranges with whiskers from the 10th to 90th percentiles representing the answers
from GPs (grey and OB/GYN (white). The black boxes represent the estimates of “true” malformation risks for each of the drugs. Statistically significant
p-values are indicated
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malformations appears consistently reproduced. One
study suggests that confounding by indication be an
issue as identical signals were found for pregnant
women pausing SSRI treatment during pregnancy
[30]. Ascertainment bias may contribute to these ob-
servations as well [31]. The clinical significance of
this increase in absolute risk of cardiovascular malfor-
mations is subject to much controversy, though most
do not believe it to preclude medical treatment [32–34].
Treating physicians are sometimes poorly helped by
regulatory information that often leads to confusion: At
the time this survey was performed, different pregnancy
labeling existed for generic variations of citalopram in
Denmark. The Summary of Product Characteristics
(SmPC) from the original marketing authorization
holder stated “…more than 2500 exposed pregnancies
does not indicate excess risk of unwanted pregnancy
outcome, but citalopram must not be used during preg-
nancy unless an absolute necessity” [35]. SPC for a gen-
eric product simply stated”… should not be used during
pregnancy as data are insufficient…” [36]. None of
these adhered to the guideline on pregnancy labeling
given the data at hand [37]. This discrepancy has later
been corrected by the Danish Health and Medicines
Authority. The perception of teratogenic potential has a
direct influence on patient compliance, and misconcep-
tions may lead to unwarranted discontinuation of anti-
depressant treatment [38, 39]. Thus, even minor
misconceptions of the teratogenic potential of citalo-
pram and sertraline may be of clinical relevance.
The risks of congenital malformations associated with
exposure to warfarin and retinoids were substantially
underestimated by GP and OB/GYN responders. This is
in contrast to other studies in which these same risks
were grossly overestimated [10, 11]. In Denmark, sys-
temic retinoids can only be prescribed by a dermatolo-
gist, and warfarin treatment is rarely initiated in women
of the fertile age without involvement of specialists in in-
ternal medicine (deep venous thrombosis) or cardiolo-
gists (heart valve replacement) [40]. Hence, the active
knowledge on teratogenic potential of these drugs is
likely to be less accurate among GP and OB/GYN.
Lamotrigine is considered safe during pregnancy, except
at very high doses, as substantial amounts of data do not
suggest an increased risk of unwanted fetal effects [41].
Responders in our study assigned risks of about 4–5 % for
congenital malformations, with similar perception of
teratogenicity among GP and OB/GYN. Lamotrigine
treatment is primarily initiated by specialists within psych-
iatry or neurology, and the active knowledge on lamotrigi-
ne's teratogenic potential among other healthcare
professionals may not be adequate. Anticonvulsants have
generally been associated with teratogenic potential, espe-
cially carbamazepine, valproate and phenytoin [41, 42].
The knowledge thereof may have had a spillover effect on
the perception of the teratogenic potential of lamotrigine
among GP and OB/GYN. The clinical importance of this
is mitigated by the same circumstances, as physicians’ ad-
vice to pregnant women receiving lamotrigine, would
likely include consulting the specialist responsible for ini-
tiation of the treatment.
This study comes with a number of limitations. While
the absolute number of responders is high compared to
most other relevant studies, the response rates in our
questionnaire are unimpressive but comparable to those
of another recent study [15]. We also have no way of de-
termining whether in fact responders only used actual
knowledge or made use of reference sources while filling
out the questionnaire. Bias in both cases would likely be
conservative as invitees may be more inclined to re-
spond if they feel that their actual knowledge on the
subject would be clinically sufficient. We were unable
to analyze results from responders and non-responders
according to demographic characteristics of interest
such as age, sex, or length of medical experience. Ac-
cordingly, generalization of our results should be made
with caution.
Conclusion
In conclusion, responders to this survey demonstrated
an understanding of teratogenic background risk and
specific risks associated with in utero exposure to 12 dif-
ferent drugs that generally approached established
knowledge. The risks associated with warfarin and retin-
oid exposure were severely underestimated by both
groups of health care professionals, while GP specifically
overestimated the risk of sertraline and citalopram.
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